髓鞘少突胶质细胞糖蛋白自身抗体检测的阳性预测值
该诊断研究在Mayo Clinic连续纳入1260例进行MOG-IgG1检测的患者,发现7.3%阳性,其中28%为假阳性,总体阳性预测值(PPV)为72%,且随滴度升高而增加;儿童、高验前概率者的PPV更高。
要点
- MOG-IgG1检测总体PPV为72%,低滴度(1:20-40)时PPV仅51%。
- 儿童PPV(94%)高于成人(67%),高验前概率者PPV(85%)高于低验前概率者(12%)。
- 低滴度阳性者需警惕假阳性,尤其在不典型表型或低验前概率时。
核心结论
- MOG-IgG1是高度特异的MOGAD生物标志物(特异性97.8%),但以1:20为 cutoff 时PPV较低(72%)。
研究设计与样本
- 诊断研究,2018年1月1日至2019年12月31日在Mayo Clinic连续纳入1260例接受活细胞法流式细胞术检测MOG-IgG1的患者,中位年龄46岁(范围0-98),女性62.9%。
主要发现
- 1260例中92例(7.3%)MOG-IgG1阳性,其中26例(28%)被判定为假阳性。
- 总体PPV为72%(95%CI 62%-80%),且呈滴度依赖性:1:1000为100%,1:100为82%,1:20-40为51%。
- 真阳性中位滴度1:100(范围1:20-1:10000)高于假阳性1:40(范围1:20-1:100),P < .001。
- 儿童PPV为94%(95%CI 72%-99%),成人67%(95%CI 56%-77%);高验前概率者PPV 85%(95%CI 76%-92%),低验前概率者12%(95%CI 3%-34%)。
关键数值与推荐
- MOG-IgG1阳性判定标准:IgG结合指数≥2.5且终点滴度≥1:20。
- 假阳性替代诊断包括多发性硬化(n=11)、梗死(n=3)、B12缺乏(n=2)、肿瘤(n=2)、遗传确诊的肾上腺脑白质营养不良(n=1)及其他(n=7)。
临床怎么用
- 临床应结合滴度和验前概率解读MOG-IgG1结果,低滴度阳性且表现不典型时需谨慎,避免在低验前概率情况下常规检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Myelin oligodendrocyte glycoprotein-IgG1-associated disorder (MOGAD) is a distinct central nervous system-demyelinating disease. Positive results on MOG-IgG1 testing by live cell-based assays can confirm a MOGAD diagnosis, but false-positive results may occur. OBJECTIVE: To determine the positive predictive value (PPV) of MOG-IgG1 testing in a tertiary referral center. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study was conducted over 2 years, from January 1, 2018, through December 31, 2019. Patients in the Mayo Clinic who were consecutively tested for MOG-IgG1 by live cell-based flow cytometry during their diagnostic workup were included. Patients without research authorization were excluded. MAIN OUTCOMES AND MEASURES: Medical records of patients who were tested were initially reviewed by 2 investigators blinded to MOG-IgG1 serostatus, and pretest probability was classified as high or low (suggestive of MOGAD or not). Testing of MOG-IgG1 used a live-cell fluorescence-activated cell-sorting assay; an IgG binding index value of 2.5 or more with an end titer of 1:20 or more was considered positive. Cases positive for MOG-IgG1 were independently designated by 2 neurologists as true-positive or false-positive results at last follow-up, based on current international recommendations on diagnosis or identification of alternative diagnoses; consensus was reached for cases in which disagreement existed. RESULTS: A total of 1617 patients were tested, and 357 were excluded. Among 1260 included patients tested over 2 years, the median (range) age at testing was 46 (0-98) years, and 792 patients were female (62.9%). A total of 92 of 1260 (7.3%) were positive for MOG-IgG1. Twenty-six results (28%) were designated as false positive by the 2 raters, with an overall agreement on 91 of 92 cases (99%) for true and false positivity. Alternative diagnoses included multiple sclerosis (n = 11), infarction (n = 3), B12 deficiency (n = 2), neoplasia (n = 2), genetically confirmed adrenomyeloneuropathy (n = 1), and other conditions (n = 7). The overall PPV (number of true-positive results/total positive results) was 72% (95% CI, 62%-80%) and titer dependent (PPVs: 1:1000, 100%; 1:100, 82%; 1:20-40, 51%). The median titer was higher with true-positive results (1:100 [range, 1:20-1:10000]) than false-positive results (1:40 [range, 1:20-1:100]; P < .001). The PPV was higher for children (94% [95% CI, 72%-99%]) vs adults (67% [95% CI, 56%-77%]) and patients with high pretest probability (85% [95% CI, 76%-92%]) vs low pretest probability (12% [95% CI, 3%-34%]). The specificity of MOG-IgG1 testing was 97.8%. CONCLUSIONS AND RELEVANCE: This study confirms MOG-IgG1 as a highly specific biomarker for MOGAD, but when using a cutoff of 1:20, it has a low PPV of 72%. Caution is advised in the interpretation of low titers among patients with atypical phenotypes, because ordering MOG-IgG1 in low pretest probability situations will increase the proportion of false-positive results.
引用
- Sechi E, Buciuc M, Pittock SJ, et al. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurol. 2021. PMID: 33900394. doi:10.1001/jamaneurol.2021.0912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。